Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an unwanted immune response. This immunogenicity may be associated with low trough drug levels, reduced clinical efficacy, reduced drug survival and an increased risk for adverse events. This article presents a literature review of the evidence on immunogenicity of biologics used in the treatment of psoriasis and considers the implications for therapeutic decision-making in the management of patients with moderate-to-severe psoriasis.

dx.doi.org/10.1111/jdv.12549, hdl.handle.net/1765/91417
Journal of the European Academy of Dermatology and Venereology
Erasmus MC: University Medical Center Rotterdam

Carrascosa, J.-M, van Doorn, M.B.A, Lahfa, M, Nestle, F.O, Jullien, D, & Prinz, J.C. (2014). Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies. Journal of the European Academy of Dermatology and Venereology. doi:10.1111/jdv.12549